Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and Older
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, vehicle-controlled, multi-center, parallel group Phase 3
study of MSRD-100 in the treatment of atopic dermatitis in subjects aged 3 months and up
Phase:
Phase 3
Details
Lead Sponsor:
Merz North America, Inc. Merz Pharmaceuticals, LLC